Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of BYON4413 in relapsed or refractory acute myeloid leukemia and myelodysplastic neoplasms
NL-OMON59268Phase 1Completed
- Sponsor
- Byondis
- Start
- Jun 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BYON4413 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Byondis. Primary endpoint: Primary endpoint(s). Started Jun 2024; status: completed.
02
Drugs
BYON4413
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON59268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59268.